ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M

ClearPoint Neuro, Inc.

2026-Q1 EPS reported -$0.32 vs consensus -$0.27 ▼ miss (-20.7%)

Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.
Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.
Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.
FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.